COVID-19 皮质类固醇治疗的患者定制化方案:仍未实现
本文指出,在 COVID-19 急性呼吸衰竭患者中,其他类固醇目前并不优于地塞米松 6 mg。自疫情初期发现皮质类固醇降低死亡率后,国际指南一致推荐住院 COVID-19 合并急性呼吸衰竭患者使用皮质类固醇,但患者定制化方案仍未实现。
要点
- 其他类固醇目前不优于地塞米松 6 mg 用于 COVID-19 急性呼吸衰竭患者。
- 国际指南基于中高质量证据一致推荐住院 COVID-19 急性呼吸衰竭患者使用皮质类固醇。
- COVID-19 皮质类固醇的患者定制化方案仍未实现。
核心结论
- 在 COVID-19 急性呼吸衰竭患者中,其他类固醇目前并不优于地塞米松 6 mg。
- COVID-19 皮质类固醇的患者定制化方案仍未实现。
主要发现
- 自疫情初期即发现 COVID-19 中失调性炎症与不良临床结局明确相关,细胞因子风暴被认为是重症的关键发病机制。
- 自 2020 年 6 月首次发表皮质类固醇降低死亡率的证据后,全身性皮质类固醇在疫情期间被广泛使用。
关键数值与推荐
- 国际指南基于中高质量证据,一致对住院 COVID-19 合并急性呼吸衰竭患者使用皮质类固醇给出中至强推荐。
- 其他类固醇目前不优于地塞米松 6 mg 用于 COVID-19 急性呼吸衰竭患者。
临床怎么用
- 对住院 COVID-19 合并急性呼吸衰竭患者,可依据国际指南推荐使用皮质类固醇。
- 其他类固醇目前不优于地塞米松 6 mg,选择时需考虑该证据背景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Other steroids are currently not superior to dexamethasone 6 mg in COVID-19 patients with acute respiratory failure https://bit.ly/3YUkc8G More than 3 years after its first appearance, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still among the most troublesome respiratory viruses and the coronavirus disease 2019 (COVID-19) pandemic is still not under control globally [1]. A clear association between dysregulated inflammation and adverse clinical outcomes has been demonstrated in COVID-19 since the very beginning of the pandemic with the so-called “cytokine storm” advocated as the key pathogenetic mechanism in severe disease [2, 3]. The scientific community theorised the use of immunomodulating agents to control this process and, among them, systemic corticosteroids have been extensively used during the pandemic since the first evidence that they reduced mortality was published in June 2020 [4]. International guidelines unanimously report moderate-to-strong recommendations in favour of corticosteroids for hospitalised COVID-19 patients with acute respiratory failure (ARF) based on moderate-to-high quality evidence [5–9].
引用
- Nigro M, Chalmers JD, Aliberti S, et al. A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet. Eur Respir J. 2023. PMID: 36858444. doi:10.1183/13993003.00270-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。